Compare Dominion Energy Inc (D) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Summit Therapeutics Inc — how do they compare? Dominion Energy Inc trades at $71.04 (market cap $62.71B), while Summit Therapeutics Inc trades at $15.01 (market cap $12.01B). The key difference: Dominion Energy Inc is far larger — about 5.2× Summit Therapeutics Inc's market cap, and Dominion Energy Inc pays a 3.74% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| D | SMMT | |
|---|---|---|
Market Cap | $62.71B | $12.01B |
Sector | Utilities | Health |
52-Week High | $71.32 | $29.32 |
52-Week Low | $56.55 | $13.05 |
Enterprise Value | $115.11B | $11.43B |
Dividend Yield | 3.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $70.8, up 1.03% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.14. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.95, and maintains a solid net income margin of 16.93%. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning D at the center of AI-driven power demand trends.
The outlook for D is mixed; upside potential exists from rising electricity demand and strategic acquisitions, but risks include regulatory scrutiny of the NextEra deal and high debt levels. Analysts are cautious, with 59% holding a neutral rating, reflecting balanced opportunities and headwinds for investors.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
